Clinical trial NCT03421912: Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)
Official title: Comparative Monocentric Randomized Study Evaluating the Satisfaction and Quality of Life of Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGRF) in Carcinomas Squamous Cells of the Head and Neck, Colorectal Cancers or Lung Cancers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Non Small Cell Lung Cancer
Epidermal Growth Factor Receptor Inhibitor
Keywords: Prevention strategy
Cutaneous toxicity
Quality of life
Patient satisfaction
Dermatology Life Quality Index (DLQI)
Epidermal Repair Score (SCOREPI)
Topical treatment
Lead sponsor: Centre Leon Berard
Sponsor class: OTHER
First posted: 2018-02-05
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Arm A : Use of Cicaplast balm B5 since de first day of iEGFR initiation treatment for 30 days Arm B : Use of Dexeryl cream since de first day of iEGFR initiation treatment for 30 days
Primary purpose: SUPPORTIVE_CARE

Brief summary: This randomized comparative study aims to evaluate the satisfaction and quality of life of patients using Cicaplast balm B5, versus Dexeryl, for the management of cutaneous toxicities of iEGFR in squamous cell carcinoma of the head and neck, cancers colorectal or pulmonary

Detailed description: The arrival of new therapeutic strategies such as targeted therapies has led to real progress in the treatment of cancers. Tyrosine kinase inhibitors and antibodies to epidermal growth factor receptors (EGFR), or iEGFR, target one of the major pathways of tumor cell proliferation. These treatments have demonstrated their interest in the treatment of certain advanced solid malignant tumors (head and neck cancer, colorectal cancer, bronchial cancer).

Although having a much better tolerance profile than the "classical" cytotoxic treatments used in the same indications, these treatments, however, have frequent cutaneous toxicities that are inconvenient for patients. According to the molecules, they can affect 80 to 90% of patients treated from the first weeks of treatment and to different degrees. They appear as well in the skin (acneiform rash, erythema, desquamation, xerosis, pruritus) as skin appendages (paronychia, alopecia).

The consequences of these adverse effects are significant, which may be at the origin of a decrease in dose or even of a stop of anti-tumoral treatment inducing a reduction of the expected clinical benefit. In addition, they represent for the patient a real source of inconvenience and pain, which can impact the quality of life (choice of dress, feeling of shame because of the appearance of the skin ...) and impact the adherence to iEGFR treatment.

Management includes first and foremost preventive measures: the use of moisturizing topicals and dermatological soap-free surgras is recommended as soon as iEGFR treatment is initiated, and preventive systemic treatment with cyclins (doxycycline 100 mg daily) is proposed for at least 6 weeks and then reevaluated for skin toxicity.

In case of appearance of skin toxicities, it is initially prescribed in common practice a topical such as Dexeryl (used in many hospitals as standard) or Cicaplast Balm B5 La Roche Posay (used in current practice at Léon Bérard Center). In a second step, topical corticosteroids are prescribed, depending on the grade of toxicity.

There is, however, no validated argument in the literature to guide the choice of clinicians to use either of these topics. Cicaplast balm B5 (antibacterial, repairing damaged skin, moisturizing and relieving feelings of discomfort) would limit the aggravation of skin toxicities and therefore the use of pharmacological measures, including topical corticosteroids class 3 or 4 may long term, weaken the skin barrier even more.

This randomized comparative study aims to evaluate the satisfaction and quality of life of patients using Cicaplast balm B5, versus Dexeryl, for the management of cutaneous toxicities of iEGFR in squamous cell carcinoma of the head and neck, cancers colorectal or pulmonary

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years.
* Patient with recurrent and / or metastatic head and neck squamous cell carcinoma OR metastatic colorectal cancer with non-mutated RAS gene (wild-type) OR non-small cell lung cancer (NSCLC) with EGFR activating mutations.
* Treated for the first time by an iEGFR having received a marketing authorization.
* Having signed a consent to participate in the study.
* Affiliated to a health insurance plan (or beneficiary of such a plan).

Exclusion Criteria:

* Concomitant radiotherapy.
* Unresolved skin toxicity from previous treatment, whatever it may be.
* Concomitant use of other topical treatments.
* Known hypersensitivity to at least one of the components of the topicals used.
* Pregnant or lactating women.
* Participation in another clinical trial (even if supportive care)

Primary outcomes:
measure: Overall patient satisfaction after 30 days treatment
timeFrame: After 30 days of treatment or at the end of treatment for patient who interrupt the treatment before 30 days
Secondary outcomes:
measure: Overall patient satisfaction after 60 days treatment
timeFrame: After 60 days of treatment or at the end of treatment for patient who interrupt the treatment before 60 days
measure: Patient Quality of life
timeFrame: At inclusion, after 30 and 60 days of treatment
measure: Cutaneous toxicities evaluation using Epidermal Repair Score (SCOREPI)
timeFrame: After 15, 30 and 60 days of treatment
measure: Cutaneous toxicities evaluation using Common Terminology Criteria for Adverse Events (CTCAE) version 4
timeFrame: After 15, 30 and 60 days of treatment
measure: Modification/Interruption/Discontinuing iEGFR treatment rate
timeFrame: Continuously up to 30 days after starting treatment
measure: DLQI and SCOREPI scores correlation
timeFrame: After 30 and 60 days of treatment
measure: Topical observance
timeFrame: Between the 1st day and the 15th day of treatment, and between the 15th and the 30th day of treatment
measure: Use rate of dermocorticoids
timeFrame: Continously up to 60 days after starting treatment
Other outcomes:
Locations:
city: Lyon
country: France
facility: Centre Léon Bérard
state: Rhône
Study officials:
affiliation: Centre Léon Bérard, Lyon, France
name: Jérôme FAYETTE, Doctor
role: PRINCIPAL_INVESTIGATOR
References: